Verona Pharma Plc’s (VRP) corporate Rating Reiterated at N+1 Singer

N+1 Singer reiterated their corporate rating on shares of Verona Pharma Plc (LON:VRP) in a research note issued to investors on Tuesday.

Other analysts have also recently issued reports about the stock. SunTrust Banks, Inc. initiated coverage on shares of Verona Pharma Plc in a research report on Monday, May 22nd. They set a buy rating and a GBX 26 ($0.33) price target for the company. Wedbush initiated coverage on shares of Verona Pharma Plc in a research report on Monday, May 22nd. They set an outperform rating and a GBX 25 ($0.32) price target for the company. Jefferies Group LLC reaffirmed a buy rating and set a GBX 250 ($3.18) price target on shares of Verona Pharma Plc in a research report on Friday, June 9th. Finally, Stifel Nicolaus initiated coverage on shares of Verona Pharma Plc in a research report on Monday, May 22nd. They set a buy rating and a GBX 22 ($0.28) price target for the company. Four research analysts have rated the stock with a buy rating, Verona Pharma Plc presently has a consensus rating of Buy and a consensus target price of GBX 80.75 ($1.03).

Verona Pharma Plc (VRP) opened at 128.56 on Tuesday. The company has a 50-day moving average price of GBX 133.19 and a 200-day moving average price of GBX 142.78. The stock’s market capitalization is GBX 66.03 million. Verona Pharma Plc has a 12-month low of GBX 120.77 and a 12-month high of GBX 210.00.

COPYRIGHT VIOLATION WARNING: This news story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/2681048/verona-pharma-plcs-vrp-corporate-rating-reiterated-at-n1-singer.html.

In other news, insider David Ebsworth acquired 13,373 shares of the firm’s stock in a transaction on Wednesday, April 26th. The stock was bought at an average cost of GBX 132 ($1.68) per share, with a total value of £17,652.36 ($22,452.76).

About Verona Pharma Plc

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company’s product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.

Receive News & Ratings for Verona Pharma Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.